Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹213 Cr
verified against source
Revenue YoY
27.27%
reported change
EBITDA
₹29.13 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Fredun Pharmaceuticals delivered a strong Q4 FY26 with revenue of ₹213 crore (+27% YoY), EBITDA of ₹29.1 crore (+67% YoY), and PAT of ₹11.1 crore (+56% YoY). EBITDA margin expanded 326 bps to 13.67%, driven by a favorable mix shift toward higher-margin new-age businesses (pet care, mobility, nutraceuticals) and operating leverage in the vintage business. Management guided for 25-30% top-line growth in FY27, with PAT margins expected to reach 10-12% over the next few years as demographic expansion for new products matures. Key growth drivers include the upcoming hormone/anti-aging product launch and the pet care platform Vagger.in. Risks include rising finance costs due to debt-funded growth and potential margin pressure from raw material inflation, though management believes these are manageable.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects overall revenue growth of 25-30% in FY27, driven by new-age businesses and steady vintage growth.
- Management targets PAT margin of 10-12% within the next few years as new-age businesses scale and demographics saturate.
- Mobility business expected to achieve ₹100 crore run-rate within 2-2.5 calendar years, and ₹250-300 crore in 5-7 years.
- Pet care e-commerce platform Vagger.in to soft-launch in mid-June and full launch in first week of July 2026.
Risks flagged
- Finance costs are elevated due to debt-funded growth; management acknowledges the need to improve cost ratios.
- Geopolitical tensions have increased raw material costs; management mitigates with buffer stock but margins could be pressured if sustained.
- Fast organic growth may stretch working capital; management claims improvement but inventory remains high at ₹270 crore.
Key quotes
- We are the only company manufacturing allopathic formulations, nutraceuticals, herbals, grooming, functional foods and also do diagnostics all under the same roof.
- Our long-term goal is very crystal clear, succinct and simple: that by 2032-2033, no pet in India can be born or die without using a Feroci product or service.
- We are not intrinsically a pharma company anymore. We are a mass market consumer product company as we speak.
Research modules